Next Article in Journal
What the Gut Tells the Brain—Is There a Link between Microbiota and Huntington’s Disease?
Next Article in Special Issue
Identification of Gene Expression Signatures for Phenotype-Specific Drug Targeting of Cardiac Fibrosis
Previous Article in Journal
Biocatalysis: An Eco-Friendly Scenario for the Manufacturing of APIs
Previous Article in Special Issue
Biglycan Involvement in Heart Fibrosis: Modulation of Adenosine 2A Receptor Improves Damage in Immortalized Cardiac Fibroblasts
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 5
10.3390/ijms24054475
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Endothelin-1 Induces Cell Proliferation and Myofibroblast Differentiation through the ETAR/Gαq/ERK Signaling Pathway in Human Cardiac Fibroblasts

by
Ratchanee Duangrat
1,2,
Warisara Parichatikanond
3,4,
Sutharinee Likitnukul
1 and
Supachoke Mangmool
1,*
1
Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
2
Molecular Medicine Graduate Program, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
3
Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand
4
Centre of Biopharmaceutical Science for Healthy Ageing (BSHA), Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(5), 4475; https://doi.org/10.3390/ijms24054475
Submission received: 16 January 2023 / Revised: 10 February 2023 / Accepted: 21 February 2023 / Published: 24 February 2023
(This article belongs to the Special Issue Cardiac Fibrosis: Molecular Pathology and Therapeutics)
Browse Figures
Versions Notes

Abstract

:
Endothelin-1 (ET-1) has been implicated in the pathogenesis of cardiac fibrosis. Stimulation of endothelin receptors (ETR) with ET-1 leads to fibroblast activation and myofibroblast differentiation, which is mainly characterized by an overexpression of α-smooth muscle actin (α-SMA) and collagens. Although ET-1 is a potent profibrotic mediator, the signal transductions and subtype specificity of ETR contributing to cell proliferation, as well as α-SMA and collagen I synthesis in human cardiac fibroblasts are not well clarified. This study aimed to evaluate the subtype specificity and signal transduction of ETR on fibroblast activation and myofibroblast differentiation. Treatment with ET-1 induced fibroblast proliferation, and synthesis of myofibroblast markers, α-SMA, and collagen I through the ETAR subtype. Inhibition of Gαq protein, not Gαi or Gβγ, inhibited these effects of ET-1, indicating the essential role of Gαq protein-mediated ETAR signaling. In addition, ERK1/2 was required for ETAR/Gαq axis-induced proliferative capacity and overexpression of these myofibroblast markers. Antagonism of ETR with ETR antagonists (ERAs), ambrisentan and bosentan, inhibited ET-1-induced cell proliferation and synthesis of α-SMA and collagen I. Furthermore, ambrisentan and bosentan promoted the reversal of myofibroblasts after day 3 of treatment, with loss of proliferative ability and a reduction in α-SMA synthesis, confirming the restorative effects of ERAs. This novel work reports on the ETAR/Gαq/ERK signaling pathway for ET-1 actions and blockade of ETR signaling with ERAs, representing a promising therapeutic strategy for prevention and restoration of ET-1-induced cardiac fibrosis.

1. Introduction

Cardiac fibrosis contributes to the abnormality of cardiac functions, leading to the development of cardiac remodeling and progression of heart failure (HF) [1,2]. The mortality and morbidity rates remain high despite recent advances in the HF therapy. HF is still a major global health problem, with the worldwide prevalence of over 64.3 million people in 2017 [3]. After cardiac injury, cardiac fibroblasts can be induced by many profibrotic factors including endothelin-1 (ET-1) in the activated form, resulting in increased fibroblast proliferation, extracellular matrix (ECM) proteins deposition, and myofibroblast differentiation [1,4,5]. Myofibroblasts are active cells which characterized by overproduction of α-smooth muscle actin (α-SMA) [5,6]. Fibroblast proliferation and myofibroblast differentiation are the hallmarks of a fibrotic response in the heart.
ET-1 is upregulated and secreted in the heart of HF patients [7] and animal models of cardiac fibrosis [8], indicating that ET-1 is a potent fibrogenic mediator. Stimulation of endothelin receptors (ETRs) with ET-1 induces myocardial fibrosis and is associated with cardiac abnormalities, leading to HF [9]. In rat cardiac fibroblasts, ET-1 induced cell proliferation, deposition of ECM, and α-SMA production as well as promoted the transdifferentiation of fibroblasts into myofibroblasts [10,11]. In contrast, myocardial fibrosis was attenuated in mice with vascular endothelial cell-specific ET-1 deficiency [12].
ETR is one of the G protein-coupled receptor (GPCR) superfamilies, denoted by endothelin receptor type A (ETAR) and type B (ETBR) [13]. Stimulation of ETRs with ET-1 promotes cell proliferation, adhesion, vasoconstriction, and fibrosis in various types of cells and tissues [13,14]. ETAR was involved in the development of fibrosis in deoxycorticosterone acetate (DOCA)-induced hypertensive rats, while ETBR mediated protective effects against vascular and renal injuries [15]. Furthermore, ET-1 induced myofibroblast differentiation and collagen matrix contraction through the ETARs, but not ETBRs, in lung fibroblasts [16]. ET-1-mediated ETAR signaling was associated with upregulation of fibronectin and matrix metalloproteinases (MMPs), as well as collagen deposition in the heart of hypertensive rats [17]. However, both ETAR and ETBR are necessary for the fibrotic effects of ET-1 by contributing to the proliferation of lung fibroblasts [18].
After ET-1 binding, the ETRs can couple to heterotrimeric Gq proteins, leading to the dissociation of Gαq and Gβγ subunits to stimulate their effectors. Consequently, Gαq proteins activate phospholipase C (PLC) activity, leading to the synthesis of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [19]. IP3 then induces the elevation of intracellular Ca2+ levels, while DAG causes protein kinase C (PKC) translocation, resulting in activation of Ras proteins, and consequently, the extracellular signal-regulated kinase (ERK) signaling pathway [20]. For example, ET-1 transduced the signaling to activation of the ERK1/2 via Gq/11 protein-dependent pathway in L6 myoblasts [21]. Interestingly, ETRs can couple with other Gα proteins, including Gαi proteins [19,22]. In addition to Gα proteins, the Gβγ subunit of ETBR provoked the PI3K/Akt/eNOS signaling pathway, resulting in nitric oxide production in endothelial cells [23]. Thus, ETRs could activate multiple signaling pathways for the induction of cardiac fibrosis, which displayed unique effects depending on receptor subtypes and Gα protein isoforms. However, it remains to be elucidated which ETR subtypes and Gα protein isoforms are involved in the ET-1-induced fibroblast stimulation and myofibroblast differentiation in human cardiac fibroblasts. In this study, we aimed to investigate how the ETR signaling pathway contributed to an induction of cardiac fibrosis. The identification of the molecular mechanisms by which ETR mediates fibroblast activation and myofibroblast differentiation (or transformation) will help us to understand this underlying pathway. Therefore, the antagonism of ETR and blockade of related signaling have been proposed to be the potential therapeutic strategy for prevention and/or treatment of cardiac fibrosis.
The important downstream effectors of ETRs include mitogen-activated protein kinases (MAPKs), such as c-Jun N-terminal kinases (JNKs), ERKs, and p38 MAPKs that contribute to the pathology of fibrotic diseases [19,22]. In vascular smooth muscle cells (VSMCs), blockade of ERK activity diminished ET-1-induced connective tissue growth factor (CTGF) production, whereas blockade of p38 MAPK had no effect [24]. Treatment with ET-1 induced ERK1/2 activation in rat cardiac myocytes [25], indicating that ERK1/2 is required for myocardial hypertrophy induced by ET-1. Moreover, ETAR regulated ERK1/2 activation via the Gq/11 protein-dependent and PLC-independent pathway in L6 myoblasts, revealing the minor contribution of PLC to ET-1-induced activation of ERK1/2 [21]. The importance of ERK1/2 for ETR signaling has been demonstrated in various types of cells; however, whether ERK1/2 is required for fibrotic effects of ET-1 in human cardiac fibroblasts has not been clearly identified.
Blockade of ETR signaling has been demonstrated to alleviate cardiac fibrosis in DOCA-induced hypertensive rats [26] and in rats with pressure overload-induced hypertrophy [27]. In addition, bosentan (a nonselective ERA) has been shown to attenuate myocardial fibrosis and remodeling in rats with myocardial infarction [28]. Long-term treatment with bosentan increased the survival rate in rats with chronic HF [29]. Administration of bosentan to HF patients led to the improvement of cardiac functions, resulting in hemodynamic benefits [30]. Interestingly, most HF patients reach clinical attention only after significant fibrosis has already been found, so reversibility of the myofibroblast differentiation process might serve as a promising tool to restore the pathology of fibrosis. In the present study, we also investigated the preventive and restorative effects of ambrisentan and bosentan on ET-1-induced fibroblast activation and myofibroblast differentiation.

2. Results

2.1. ET-1 Induces Cell Proliferation, and Expression of α-SMA and Collagen I in a Dose-Dependent Manner

We first assessed the profibrotic effects of ET-1 on fibroblast activation and myofibroblast differentiation as determined by cell proliferation, and collagen I and α-SMA synthesis in fetal human cardiac fibroblasts. Cells were incubated with different doses of ET-1 (1–20 nM) for 24 h. Stimulation of ETRs with ET-1 led to a significant increase in the amounts of fibroblasts in a dose-dependent manner that showed the highest efficacy at a dose of 20 nM (Figure 1A). To further identify the proliferative capacity of ET-1, we used Ki-67 nuclear staining as a marker of proliferation. The density of Ki-67-positive fibroblast cells was generally low in non-treated fibroblasts (Figure 1B). Treatment with ET-1 significantly increased the Ki-67-positive fibroblasts, as shown by the green color in a dose-dependent way (Figure 1B). Myofibroblasts are highly active cells that overexpress α-SMA and collagen I. We next investigated the effects of ET-1 on collagen I and α-SMA synthesis and found that treatment with ET-1 resulted in a significant increase in α-SMA protein and mRNA expression, as well as collagen I mRNA expression in a dose-dependent manner, which showed the maximal effect at the concentration of 20 nM (Figure 1C,D). These results demonstrate that stimulation of ETRs enhanced the cell proliferation and the synthesis of α-SMA and collagen I of human cardiac fibroblasts. In addition, treatment with ET-1 for 24 h and up to 48 h increased the number of fibroblasts as well α-SMA protein expression (Supplementary Figure S1).

2.2. ET-1-Induced Fibroblast Proliferation, and Synthesis of α-SMA and Collagen I Mediated through the ETAR Subtype

The biological effects of ET-1 are derived from activation of ETRs, which exist in ETARs and ETBRs. We used a selective ETAR antagonist (ambrisentan), and a selective ETBR antagonist (BQ-788) to identify which ETR subtypes are associated with the fibrotic effects of ET-1 in human cardiac fibroblasts. Pretreatment with ambrisentan significantly inhibited ET-1-induced cell proliferation (Figure 2A,B), and synthesis of α-SMA and collagen I (Figure 2C,D), whereas BQ-788 had no effects. Blockade of both ETR subtypes completely inhibited these ET-1 effects (Figure 2). Treatment with these antagonists alone had no effect on cell proliferation and did not cause cell cytotoxicity (Supplementary Figure S2). These data revealed that stimulation of ETARs, not ETBRs, induced fibroblast activation and myofibroblast transdifferentiation.

2.3. Gαq protein Is Responsible for ETAR-Mediated Cell Proliferation and Myofibroblast Differentiation

ETAR is classified as a Gq protein-coupled receptor which transduces the signals mediated through heterotrimeric Gq proteins. After ET-1 binding, the ETAR interact with heterotrimeric Gq proteins, leading to the dissociation of the Gαq protein from the Gβγ subunit [19]. Not only coupling with Gq protein, ETARs also couple with the Gi protein [19,22]. Pertussis toxin (PTX) is widely used for inhibition of the Gi/o protein by catalyzing the ADP-ribosylation of the α subunit of Gi/o protein [31]. We used specific inhibitors of Gα protein activities, including FR900359 (Gq inhibitor), and PTX (Gi/o inhibitor) to identify which isoform of Gα proteins mediates ETR signaling. As shown in Figure 3, blockade of Gq signaling using FR900359 significantly reduced ET-1-induced fibroblast proliferation and the synthesis of α-SMA and collagen I, whereas inhibition of Gi signaling using PTX had no effect.
We also used gallein, a specific Gβγ inhibitor, to investigate whether Gβγ subunits play a critical role in ET-1-mediated cardiac fibrosis. We found that gallein did not inhibit ET-1 actions (Figure 3). Additionally, these inhibitors had no effect on cell proliferation and did not cause cell cytotoxicity (Supplementary Figure S2). Taken together, these data suggest that ET-1 exhibits profibrotic effects through the ETAR/Gαq axis.

2.4. ERK1/2 Is Necessary for ET-1-Induced Fibroblast Activation and Myofibroblast Differentiation

MAPKs have been associated with ETR signaling. ET-1 can activate MAPKs such as ERKs, JNKs, and p38 MAPKs that contribute to the pathology of fibrotic diseases [19,22]; therefore, we examined whether the profibrotic effects of ET-1 are mediated through MAPKs by using specific inhibitors, SP600125 (JNK inhibitor), FR180204 (ERK1/2 inhibitor), and SB203580 (p38 MAPK inhibitor).
We first tested the cytotoxic effects of each inhibitor and found that SP600125, FR180204, and SB203580 did not cause cell cytotoxicity (Supplemental Figure S2). We found that the blockade of ERK1/2 activity significantly inhibited ET-1-induced fibroblast proliferation (Figure 4A,B), and α-SMA and collagen I synthesis (Figure 4C,D). In contrast, inhibitions of p38 MAPKs and JNKs had no effect on ET-1 actions. Hence, ET-1 stimulation of ETR induced cardiac fibrosis in a ERK1/2-dependent way. Since the treatment with ET-1 could induce ERK1/2 activation in rat cardiac fibroblasts [32,33], we next determined the effects of ET-1 on ERK1/2 activation by measurement of the phosphorylated ERK1/2 levels in human cardiac fibroblasts. Treatment fibroblasts with ET-1 dramatically increased the phosphorylated ERK1/2 (p-ERK1/2) levels (Figure 4E). Pretreatment with ambrisentan (a selective ETAR antagonist) markedly suppressed the ET-1-induced ERK1/2 phosphorylation, whereas BQ788 (a selective ETBR antagonist) had no effect (Figure 4E). Moreover, ET-1-induced ERK1/2 phosphorylation was dramatically reduced by FR900359 (specific Gαq inhibitor) (Figure 4F). All original immunoblots were presented in Supplementary Figure S3. However, blockades of Gαi signaling using PTX and Gβγ signaling using gallein failed to inhibit ET1-induced ERK1/2 phosphorylation (Figure 4F). Taken together, these data suggest that activation of ERK1/2 by ET-1 occurs via an ETAR/Gαq-dependent pathway.

2.5. ERAs Prevent ET-1-Induced Fibroblast Proliferation and Myofibroblast Differentiation

According to our present data showing the stimulation of ETARs induced fibroblast activation and myofibroblast differentiation, we next investigated the preventive effects of currently approved ERAs, ambrisentan and bosentan, on the effects of ET-1. Blockade of ETARs with these ERAs completely inhibited ET-1-induced fibroblast proliferation, and α-SMA and collagen synthesis in human cardiac fibroblasts (Figure 5). Together, these data indicated that ambrisentan and bosentan exhibit preventive effects on the inhibition of ET-1-induced cardiac fibrosis.

2.6. ERAs Reverse Myofibroblast Differentiation Induced by ET-1

It has been shown that anti-fibrotic agents such as prostaglandin E2 (PGE2) [34] and metformin [35] can reverse the myofibroblast phenotype of lung fibroblasts. However, the effects of ERAs on the reversibility of myofibroblasts of human cardiac fibroblasts are unknown. We investigated the restorative effects of ambrisentan and bosentan on ET-1-mediated fibroblast proliferation and α-SMA synthesis. Firstly, normal fibroblasts were activated and differentiated into myofibroblasts which were characterized by increasing proliferative capacity and overexpression of α-SMA by treatment with ET-1 for 24 h. After ET-1 stimulation, the culture medium was removed and changed with fresh medium containing ET-1 plus vehicle or ET-1 plus ERAs, and cells were further cultured for 3 days and assessed for cell proliferation and α-SMA expression at days 1 and 3 (Figure 6A).
ET-1 treatment for 24 h induced fibroblast proliferation and α-SMA expression, indicating the state of myofibroblast differentiation in human cardiac fibroblasts. After changing the medium the cells were further cultured for 1 or 3 days. In absence of ERAs, proliferative capacity and overexpression of α-SMA were persistent and stable for up to 3 days (Figure 6B–D). In contrast, co-treatment with ERAs exhibited the restorative effects in a time-dependent decrease in proliferative capacity and α-SMA expression. The maximal restorative effects of ambrisentan and bosentan were observed at day 3 after ERAs addition (Figure 6B–D). These results suggested that blockade of ETARs with ERAs exhibits restorative effects on the reversal of myofibroblast phenotypes, as shown by a reduction in the proliferative capacity and α-SMA expression.

3. Discussion

Endothelin comprises three isoforms, ET-1, ET-2, and ET-3; ET-1 is mainly synthesized by endothelial cells and in cardiomyocytes as well as cardiac fibroblasts [36]. ET-1 is a potent vasopressor and exerts a positive inotropic effect on the human heart [37]. However, prolonged and overstimulation of ETRs with ET-1 plays a critical role in heart abnormalities, including cardiac fibrosis. In the heart of rats with myocardial infarction, myofibroblasts found at the site of infarction expressed preproendothelin-1, endothelin-converting enzymes and ETRs [38]. The synthesized ET-1 induced collagen I production [38]. These data indicated that the ET-1 system plays a critical role in cardiac fibrosis and remodeling, therefore, blockade of ETR signaling by using specific inhibitors is of intense interest because they represent the potential treatment and prevention of fibrosis in the heart.
ET-1 is able to induce myofibroblast phenotypes from resident fibroblasts, which are characterized by α-SMA and collagen overexpression [22]. In addition, the myofibroblast phenotype exhibits several capabilities, such as contractility, migration, proliferation, and production and deposition of ECM proteins such as collagens [22]. For instance, ET-1 induced α-SMA and collagen synthesis through the ETARs, but not ETBRs in lung fibroblasts [16]. Treatment with ET-1 induced cell proliferation and α-SMA synthesis in alveolar fibroblasts, and neutralization of ET-1 with a monoclonal antibody was able to inhibit fibroblast proliferation [39]. Elevation of ET-1 levels was found in bronchoalveolar lavage fluid (BALF) from patients with systemic sclerosis, and this BALF containing ET-1 induced an increase in the proliferative capacity of lung fibroblasts [18]. Consistent with these previous studies, in this report we demonstrated that prolonged treatment with ET-1 up to 48 h increased proliferative capacity and induced myofibroblast differentiation as determined by α-SMA and collagen I overexpression in human cardiac fibroblasts. Even though α-SMA and collagen I are widely used for myofibroblast identifications, the other biomarkers, such as actin stress fiber formation, should be used to confirm the myofibroblast phenotype.
There are two subtypes of ETR, ETAR and ETBR, which are found in cardiac fibroblasts [40]. Both are members of the GPCR superfamily, which transduces the signals mediated through heterotrimeric G proteins affecting cardiac functions and cardiovascular disorders, including hypertension, myocardial hypertrophy, and fibrosis [22]. ET-1 induced DNA synthesis through the ETAR subtype in rat cardiac fibroblasts, contributing to fibroblast proliferation [33]. In addition, ET-1 induced upregulation of CTGF synthesis via ETARs in VSMCs [24]. Blockade of ETAR with BQ123 (a specific ETAR antagonist) inhibited ET-1-induced protein synthesis in cardiac myocytes, while BQ788 (a specific ETBR antagonist) had no effect [41]. In neonatal rat cardiomyocytes, treatment with ET-1 induced myocyte hypertrophy and upregulation of hypertrophic genes in an ETAR-dependent way [25]. Although most of the detrimental effects of ET-1 are mediated via the ETAR, the ETBR may be also important. Both ETARs and ETBRs induced vasoconstriction of human resistance and capacitance vessels [42]. The actions of endothelin on the upregulation of collagens were mediated through ETARs and ETBRs, while their actions of the downregulation of collagenase seem to be mediated through ETARs [43]. Even though the ETBRs are also required for vasoconstriction and collagen synthesis, and ETBRs were upregulated in fibrotic-related diseases, such as scleroderma-associated fibrotic lung disease [44] and pulmonary arterial hypertension [45], our present study revealed that the ETBRs did not involve in the profibrotic effects of ET-1 in human cardiac fibroblasts.
ET-1 binding to the ETRs leads the dissociation of activated Gαq protein from the Gβγ dimer, resulting in an activation of PLC and subsequent generation of IP3 and DAG [19]. Elevation of IP3 levels leads to the activation of the Ca2+-dependent signaling pathway, while DAG induces translocation of PKC, resulting in Ras-mediated ERK1/2 activation in cardiac myocytes [20,46]. Furthermore, ERK1/2 activation by ET-1 was abolished by YM-254890 (a Gαq/11 protein inhibitor), indicating the important role of the Gαq/11 protein for ET-1-induced ERK1/2 cascade in rat L6 myoblasts [21]. Not only the Gαq protein, but also ETRs coupled with other isoforms, such as Gαi proteins, indicating that ETRs might transduce the distinct signaling pathway via multiple types of heterotrimeric G proteins [19,22]. In addition to the Gα protein-dependent pathway, the Gβγ dimer can transduce the signaling by itself. For example, the Gβγ subunit of ETBR can provoke the PI3K/Akt/eNOS signaling pathway, resulting in nitric oxide production in endothelial cells [23]. Using specific inhibitors of heterotrimeric G proteins, we found that cell proliferation, and α-SMA and collagen I synthesis induced by ET-1 were abolished by FR900359 (Gq inhibitor), but not PTX (Gi inhibitor), or gallein (Gβγ inhibitor) (Figure 3) Our data imply that ETAR stimulation induced fibroblast activation and myofibroblast differentiation through a Gαq-dependent pathway. Interestingly, the ETR/Gαq axis has been reported to stimulate ERK1/2 activity through the transactivation of platelet derived growth factor receptors (PDGFRs) [21] in rat myoblasts and epidermal growth factor receptors (EGFRs) in various types of cells, including cardiomyocytes [47] and rat-1 fibroblasts [48]. However, the role of ET-1 on transactivation of these growth factor receptors in human cardiac fibroblasts is not known. It will require further studies to identify the precise mechanistic details of ETR/Gq compartmentation and whether growth factor receptors are assembled within this complexity for ERK1/2 activation.
Among three MAPKs, ERKs have extensively involved in the fibrosis and hypertrophy. In VSMCs, inhibition of ERK1/2 activity markedly suppressed ET-1-induced CTGF synthesis, whereas blockade of p38 MAPK had no effect [24], indicating that ET-1 regulates CTGF, which is a profibrotic mediator in an ERK-dependent pathway in vascular diseases. In addition, blockade of ERK activity using U0126 inhibited ET-1-induced ET-1 gene expression, while inhibition of either JNK or p38 MAPK had no effect, indicating that the Ras-Raf-ERK signaling pathway is necessary for ET-1 action in rat cardiac fibroblasts [33]. In agreement with these studies, our study reported that inhibition of ERK1/2 activity attenuated ET-1-induced fibroblast proliferation and myofibroblast differentiation, while inhibition of JNK and p38 MAPK had no effect. Antagonism of ETARs and blockade of Gαq-dependent signaling were able to inhibit ET-1-induced ERK1/2 phosphorylation in human cardiac fibroblasts (Figure 4E,F). Therefore, our data and other studies suggest the essential role for the ETAR/Gαq/ERK pathway for ET-1-mediated cardiac fibrosis.
Although ERAs (e.g., ambrisentan, bosentan, and macitentan) are only approved for the treatment of pulmonary arterial hypertension, they have been extensively studied in both animal and clinical experiments for their essential role in the treatment of fibrotic-related fibrosis, including cardiac fibrosis. For example, treatment with ERAs reduced cardiac remodeling in animal models of infarctive and hypertensive cardiac fibrosis [27,28]. Bosentan improved cardiac functions and reduced infarct size after myocardial ischemia/reperfusion injury in rats [28]. Furthermore, administration of bosentan improved cardiac functions, leading to hemodynamic benefits in patients with HF [30]. Here we also demonstrated that ambrisentan and bosentan suppressed ET-1-induced fibroblast activation and myofibroblast differentiation in human cardiac fibroblasts. Both ERAs showed similar preventive effects, and could help to prevent cardiac fibrosis induced by ET-1.
Unfortunately, many patients with fibrotic disorders, including HF, expressed signs and symptoms and reached clinical care after significant fibrosis has already advanced [1,49]. Interestingly, many studies have reported that the myofibroblast differentiation process can be reversed [50,51]. For these HF patients, reversal of myofibroblast differentiation (so called dedifferentiation) represents attractive therapeutic strategies to already established myocardial fibrosis [52]. Even though many anti-fibrotic agents possess the ability to reverse the myofibroblast differentiation in lung fibroblasts such as PGE2 [34] and metformin [35], the effects of ambrisentan and bosentan on the reversal of myofibroblast differentiation are unknown. In our present study, we report that ambrisentan and bosentan promote dedifferentiation of myofibroblasts after day 3 of treatment, with loss of proliferative capacity, and reduce the expression of α-SMA, indicating the restorative effects of these ERAs in human cardiac fibroblasts (Figure 6). These preventive and restorative effects of ERAs provide the current trends of approach in attenuating and recovering cardiac fibrosis and could potentially be achieved. It should be noted that our results have come from the study using cardiac fibroblasts. The animal models of myocardial fibrosis should be performed to confirm the underlying mechanism of profibrotic effects of ET-1 as well as the preventive and restorative effects of ERAs.

4. Materials and Methods

4.1. Materials

Ambrisentan, bosentan, pertussis toxin (PTX), 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), SB203580 (p38 MAPK inhibitor), SP600125 (JNK inhibitor), and FR180204 (ERK1/2 inhibitor) were obtained from Sigma-Aldrich (Saint Louis, MO, USA). ET-1, BQ788 (ETBR antagonist), and gallein (Gβγ inhibitor) were purchased from Tocris Bioscience (Ellisville, MO, USA). FR900359 (Gαq inhibitor) was obtained from Cayman Chemical (Ann Arbor, MI, USA). Fibroblast medium and related cell culture reagents were purchased from Cell Applications (San Diego, CA, USA). Ambrisentan, bosentan, SB2033580, SP600125, FR180204, gallein, and BQ788 were dissolved in dimethyl sulfoxide (DMSO), whereas endothelin-1 and PTX were dissolved in distilled water when preparing the stock solutions. Aliquots of stock solution were stored at −20 °C.

4.2. Cell Culture

Human cardiac fibroblasts (catalog no. 306-05f) were obtained from Cell Applications and were cultured at 37 °C/5% CO2 in fibroblast growth medium containing 1% penicillin/streptomycin (P/S) solution as described previously [53]. The cells between passages 3 and 5 were subjected to all experiments.

4.3. Measurement of Cell Proliferation by MTT Assay

Fibroblasts (5 × 103 cells/well) were cultured in 96-well plates containing medium supplemented with 1% growth serum and 1% P/S. Afterward, fibroblasts were incubated with specific inhibitors for 1 h before stimulation with ET-1 for 24 or 48 h. After stimulation, the medium was discarded and cells were further incubated with MTT solution (1 mg/mL) for 4 h. After incubation, dimethyl sulfoxide (100 μL/well) was added and thoroughly mixed to dissolve the formazan crystals [11]. Finally, the absorbance of the solution was monitored by an EZ Read 400 microplate reader (Biochrom, Cambridge, UK) at 570 nm wavelength. The formula below was used to calculate the numbers of viable cells.
Cell viability (%) = (Absorbance of treated cells/Absorbance of non-treated cells) × 100.

4.4. Measurement of Proliferative Capacity by Ki-67 Staining Assay

Ki-67 is present in all active phases of cell cycle (e.g., G1, S and G2), and mitosis, but is absent in G0 phase (resting state). Ki-67 is used for determining the proliferative capacity of the cells. Fibroblasts (1 × 104 cells/well) were cultured in 12-well plates containing gelatin-coated coverslips. After stimulation, cells were fixed with 4% paraformaldehyde (PFA) overnight and washed with phosphate-buffered saline (PBS) before permeabilized with 0.1% Triton X-100 solution for 5 min. Cells were washed with PBS, incubated with 1% bovine serum albumin (BSA) for 30 min, and stained with Ki-67 conjugated-FITC antibody (1:200, Invitrogen) for 1 h. After washing, the coverslips containing cells were mounted onto microscope slides with DAPI containing Antifade Mountant (Invitrogen, Carlsbad, CA, USA). The samples were imaged by fluorescence microscope (Nikon Eclipse Ts2R; 20X objective lens, Tokyo, Japan) at 488/520 nm for excitation and emission wavelength, respectively. Three to five different images were taken per each group of treatment. Cell proliferation indices were determined by counting at least 100 cells from 3–4 randomly selected images. The Ki-67 score is defined as the ratio of Ki-67-positive cells (green) to the total counted cells.

4.5. Detection of α-SMA Expression by Fluorescence Microscopy

Fibroblasts (1 × 104 cells/well) were cultured in 12-well plates containing gelatin-coated cover slips. After stimulation, cells were fixed with 4% PFA overnight and washed with PBS before permeabilized with 0.1% Triton X-100 for 5 min [54]. After blocking with 1% BSA for 30 min, cells were incubated with anti-α-SMA antibody (1:250, Sigma-Aldrich) for 1 h. After washing, cells were incubated with anti-mouse Alexa Fluor 488 secondary antibody (Invitrogen) for 1 h. After washing, the coverslips containing cells were mounted onto microscope slides with DAPI containing Antifade Mountant (Invitrogen). The α-SMA protein expression was detected by fluorescence microscope (Nikon Eclipse Ts2R; 20X objective lens) at 488/520 nm. Three to five different images were taken per each group of treatment.

4.6. Western Blotting

Fibroblasts (2 × 105 cells/well) were cultured in 6-well plate. Cells were pretreated with various inhibitors before stimulation with ET-1 in serum-free media condition. After stimulation, cells were rinsed with cold PBS, then lysed with Triton X-100 lysis buffer (containing: 0.8% Triton X-100, 20 mM Tris-HCl, 2 mM EDTA, 150 mM NaCl, and protease inhibitor cocktail) for 2 h with gentle rotation, followed by centrifugation at 14,000 rpm at 4 °C for 15 min [55]. The supernatants were then collected, and protein levels were measured by Bradford protein assay (Bio-Rad, Hercules, CA, USA). The equal amounts of protein samples in SDS loading buffer were heated for 5 min, and subjected to 10% SDS-PAGE. After that, protein samples from gels were transferred to PVDF membranes and incubated with 2% BSA for 1 h. After blocking with 2% BSA, membranes were incubated with primary antibodies against p-ERK-1/2 (1:2000, Cell signaling, Danvers, MA, USA), ERK-1/2 (1:2000, Cell signaling), and β-actin (1:3000, Cell signaling) overnight. After washing with tris-buffered saline with Tween 20 (TBST), membranes were incubated with anti-rabbit HRP-conjugated antibody (1:3000, Amersham Biosciences, Buckinghamshire, UK). After washing with TBST, membranes were soaked in chemiluminescence substrate (SuperSignal West Pico PLUS, Thermo Scientific, Waltham, MA, USA) and then exposed to a GelDoc XR imaging system (Bio-Rad). The band intensity was analyzed using Image J software (version 1.53k, NIH, Bethesda, MD, USA).

4.7. mRNA Expression Analysis by Real-Time qRT-PCR

Total RNA was extracted with GeneJET RNA isolation kits (Thermo scientific). The qRT-PCR was performed by the AriaMx Real Time PCR system (Agilent Technologies, Santa Clara, CA, USA) using the Brilliant III ultra-fast SYBR green qRT-PCR master mix (Agilent Technologies) [56]. The human primers were designed and purchased from Macrogen (Seoul, Republic of Korea) as follow; α-SMA (sense, 5′- tggctattccttcgttactactgct-3′; antisense, 5′-catcaggcaactcgtaactcttctc-3′), collagen I (sense, 5′-ctgctggacgtcctggtgaa-3′; antisense, 5′-acgctgtccagcaataccttgag-3′), and β-actin (sense, 5′-gtggccgaggactttgattg-3′; antisense, 5′-agtggggtggcttttaggatg-3′). The α-SMA and collagen I mRNA levels were normalized to β-actin and expressed as the fold over the vehicle-treated group based on the comparative cycle threshold (2−ΔΔCT) assay [57].

4.8. Data Analysis

The results were expressed as the mean ± SD from 4 independent experiments. Statistical significance among different groups was determined by Student’s t-test and one-way ANOVA with Tukey’s post hoc test. The statistical analyses were evaluated with GraphPad PrismTM (version 6.0). A p value less than 0.05 (p < 0.05) was considered to represent significant differences.

5. Conclusions

The results of our present study provide an essential role for the ERK1/2 signaling pathway for ET-1-induced fibroblast activation and myofibroblast differentiation in human cardiac fibroblasts. The ET-1 effects appear to be predominantly mediated by the ETAR subtype. Moreover, Gαq protein is required for ETAR-mediated ERK1/2 activation (Figure 7). Our data support the concept whereby ETAR stimulation contributes to the progression of cardiac fibrosis in HF patients. In addition, ETR antagonism using ERAs, ambrisentan and bosentan, exhibits cardioprotective effects by prevention and restoration of ET-1-induced fibroblast proliferation and α-SMA synthesis.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24054475/s1.

Author Contributions

Conceptualization, W.P. and S.M.; methodology, R.D., W.P. and S.M.; validation, R.D. and S.M.; formal analysis, R.D., W.P., S.L. and S.M.; investigation, S.M.; resources, S.L., W.P. and S.M.; data curation, R.D. and W.P.; writing—original draft preparation, R.D. and S.M.; writing—review and editing, R.D., W.P., S.L. and S.M.; visualization, R.D. and S.M.; supervision, S.M.; project administration, S.M.; funding acquisition, R.D. and S.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by grants from the National Research Council of Thailand (NRCT) and Mahidol University [Grant number NRCT5-RSA63015-07]; the CIF and CNI grant from the Faculty of Science, Mahidol University (to S.M.); Mahidol University under the New Discovery and Frontier Research Grant [grant number NDFR 32/2564] (to W.P.); and the Science Achievement Scholarship of Thailand (SAST) from the Office of the Higher Education Commission (OHEC) (to R.D.).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data generated or analyzed during the current study are included in this published article and its supplementary information file.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Frangogiannis, N.G. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol. Asp. Med. 2019, 65, 70–99. [Google Scholar] [CrossRef] [PubMed]
  2. Parichatikanond, W.; Luangmonkong, T.; Mangmool, S.; Kurose, H. Therapeutic targets for the treatment of cardiac fibrosis and cancer: Focusing on TGF-β signaling. Front. Cardiovasc. Med. 2020, 7, 34. [Google Scholar] [CrossRef] [PubMed]
  3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Jiang, W.; Xiong, Y.; Li, X.; Yang, Y. Cardiac fibrosis: Cellular effectors, molecular pathways, and exosomal roles. Front. Cardiovasc. Med. 2021, 8, 715258. [Google Scholar] [CrossRef] [PubMed]
  5. Czubryt, M.P. Cardiac fibroblasts to myofibroblast phenotype conversion:An unexploited therapeutic target. J. Cardiovasc. Dev. Dis. 2019, 6, 28. [Google Scholar] [CrossRef] [Green Version]
  6. Kurose, H.; Mangmool, S. Myofibroblasts and inflammatory cells as players of cardiac fibrosis. Arch. Pharm. Res. 2016, 39, 1100–1113. [Google Scholar] [CrossRef]
  7. Tsutamoto, T.; Wada, A.; Maeda, K.; Mabuchi, N.; Hayashi, M.; Tsutsui, T.; Ohnishi, M.; Sawaki, M.; Fujii, M.; Matsumoto, T.; et al. Transcardiac extraction of circulating endothelin-1 across the failing heart. Am. J. Cardiol. 2000, 86, 524–528. [Google Scholar] [CrossRef] [PubMed]
  8. Yamamoto, K.; Masuyama, T.; Sakata, Y.; Mano, T.; Nishikawa, N.; Kondo, H.; Akehi, N.; Kuzuya, T.; Miwa, T.; Hori, M. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc. Res. 2000, 47, 274–283. [Google Scholar] [CrossRef] [Green Version]
  9. Mueller, E.E.; Momen, A.; Masse, S.; Zhou, Y.Q.; Liu, J.; Backx, P.H.; Henkelman, R.M.; Nanthakumar, K.; Stewart, D.J.; Husain, M. Electrical remodelling precedes heart failure in an endothelin-1-induced model of cardiomyopathy. Cardiovasc. Res. 2011, 89, 623–633. [Google Scholar] [CrossRef]
  10. Nishida, M.; Onohara, N.; Sato, Y.; Suda, R.; Ogushi, M.; Tanabe, S.; Inoue, R.; Mori, Y.; Kurose, H. Gα12/13-mediated up-regulation of TRPC6 negatively regulates endothelin-1-induced cardiac myofibroblast formation and collagen synthesis through nuclear factor of activated T cells activation. J. Biol. Chem. 2007, 282, 23117–23128. [Google Scholar] [CrossRef] [Green Version]
  11. Phosri, S.; Arieyawong, A.; Bunrukchai, K.; Parichatikanond, W.; Nishimura, A.; Nishida, M.; Mangmool, S. Stimulation of adenosine A2B receptor inhibits endothelin-1-induced cardiac fibroblast proliferation and α-smooth muscle actin synthesis through the cAMP/Epac/PI3K/Akt-signaling pathway. Front. Pharmacol. 2017, 8, 428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Adiarto, S.; Heiden, S.; Vignon-Zellweger, N.; Nakayama, K.; Yagi, K.; Yanagisawa, M.; Emoto, N. ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci. 2012, 91, 651–657. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Davenport, A.P.; Hyndman, K.A.; Dhaun, N.; Southan, C.; Kohan, D.E.; Pollock, J.S.; Pollock, D.M.; Webb, D.J.; Maguire, J.J. Endothelin. Pharmacol. Rev. 2016, 68, 357–418. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Lüscher, T.F.; Barton, M. Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, 102, 2434–2440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Matsumura, Y.; Hashimoto, N.; Taira, S.; Kuro, T.; Kitano, R.; Ohkita, M.; Opgenorth, T.J.; Takaoka, M. Different contributions of endothelin-A and endothelin-B Receptors in the pathogenesis of deoxycorticosterone acetate–salt–induced hypertension in rats. Hypertension 1999, 33, 759–765. [Google Scholar] [CrossRef] [Green Version]
  16. Shi-Wen, X.; Chen, Y.; Denton, C.P.; Eastwood, M.; Renzoni, E.A.; Bou-Gharios, G.; Pearson, J.D.; Dashwood, M.; du Bois, R.M.; Black, C.M.; et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell 2004, 15, 2707–2719. [Google Scholar] [CrossRef] [Green Version]
  17. Ammarguellat, F.Z.; Gannon, P.O.; Amiri, F.; Schiffrin, E.L. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: Role of ETA receptors. Hypertension 2002, 39, 679–684. [Google Scholar] [CrossRef] [Green Version]
  18. Cambrey, A.D.; Harrison, N.K.; Dawes, K.E.; Southcott, A.M.; Black, C.M.; du Bois, R.M.; Laurent, G.J.; McAnulty, R.J. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell Mol. Biol. 1994, 11, 439–445. [Google Scholar] [CrossRef]
  19. Horinouchi, T.; Terada, K.; Higashi, T.; Miwa, S. Endothelin receptor signaling: New insight into its regulatory mechanisms. J. Pharmacol. Sci. 2013, 123, 85–101. [Google Scholar] [CrossRef] [Green Version]
  20. Kennedy, R.A.; Kemp, T.J.; Sugden, P.H.; Clerk, A. Using U0126 to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes. J. Mol. Cell. Cardiol. 2006, 41, 236–247. [Google Scholar] [CrossRef]
  21. Harada, T.; Horinouchi, T.; Higa, T.; Hoshi, A.; Higashi, T.; Terada, K.; Mai, Y.; Nepal, P.; Horiguchi, M.; Hatate, C.; et al. Endothelin-1 activates extracellular signal-regulated kinases 1/2 via transactivation of platelet-derived growth factor receptor in rat L6 myoblasts. Life Sci. 2014, 104, 24–31. [Google Scholar] [CrossRef] [PubMed]
  22. Rodríguez-Pascual, F.; Busnadiego, O.; González-Santamaría, J. The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases? Life Sci. 2014, 118, 156–164. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Liu, S.; Premont, R.T.; Kontos, C.D.; Zhu, S.; Rockey, D.C. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat. Med. 2005, 11, 952–958. [Google Scholar] [CrossRef] [PubMed]
  24. Rodriguez-Vita, J.; Ruiz-Ortega, M.; Rupérez, M.; Esteban, V.; Sanchez-López, E.; Plaza, J.J.; Egido, J. Endothelin-1, via ETA receptor and independently of transforming growth factor-β, increases the connective tissue growth factor in vascular smooth muscle cells. Circ. Res. 2005, 97, 125–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Archer, C.R.; Robinson, E.L.; Drawnel, F.M.; Roderick, H.L. Endothelin-1 promotes hypertrophic remodelling of cardiac myocytes by activating sustained signalling and transcription downstream of endothelin type A receptors. Cell Signal. 2017, 36, 240–254. [Google Scholar] [CrossRef]
  26. Ammarguellat, F.; Larouche, I.; Schiffrin, E.L. Myocardial fibrosis in DOCA-salt hypertensive rats: Effect of endothelin ETA receptor antagonism. Circulation 2001, 103, 319–324. [Google Scholar] [CrossRef] [Green Version]
  27. Visnagri, A.; Kandhare, A.D.; Ghosh, P.; Bodhankar, S.L. Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibrosis in pressure overload-induced cardiac hypertrophy in rats. Cardiovasc. Endocrinol. Metab. 2013, 2, 85–97. [Google Scholar] [CrossRef]
  28. Singh, A.D.; Amit, S.; Kumar, O.S.; Rajan, M.; Mukesh, N. Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats. Basic Clin. Pharmacol. Toxicol. 2006, 98, 604–610. [Google Scholar] [CrossRef]
  29. Mulder, P.; Richard, V.; Derumeaux, G.; Hogie, M.; Henry, J.P.; Lallemand, F.; Compagnon, P.; Macé, B.; Comoy, E.; Letac, B.; et al. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997, 96, 1976–1982. [Google Scholar] [CrossRef]
  30. Sütsch, G.; Kiowski, W.; Yan, X.W.; Hunziker, P.; Christen, S.; Strobel, W.; Kim, J.H.; Rickenbacher, P.; Bertel, O. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998, 98, 2262–2268. [Google Scholar] [CrossRef] [Green Version]
  31. Mangmool, S.; Kurose, H. Gi/o protein-dependent and-independent actions of pertussis toxin (PTX). Toxins 2011, 3, 884–899. [Google Scholar] [CrossRef] [Green Version]
  32. Chen, C.; Cheng, T.; Lin, H.; Shih, N.; Chen, Y.; Chen, Y.; Cheng, C.; Lian, W.; Meng, T.; Chiu, W.; et al. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol. Pharmacol. 2006, 69, 1347–1355. [Google Scholar] [CrossRef] [Green Version]
  33. Cheng, C.M.; Hong, H.J.; Liu, J.C.; Shih, N.L.; Juan, S.H.; Loh, S.H.; Chan, P.; Chen, J.J.; Cheng, T.H. Crucial role of extracellular signal-regulated kinase pathway in reactive oxygen species-mediated endothelin-1 gene expression induced by endothelin-1 in rat cardiac fibroblasts. Mol. Pharmacol. 2003, 63, 1002–1011. [Google Scholar] [CrossRef]
  34. Garrison, G.; Huang, S.K.; Okunishi, K.; Scott, J.P.; Kumar Penke, L.R.; Scruggs, A.M.; Peters-Golden, M. Reversal of myofibroblast differentiation by prostaglandin E2. Am. J. Respir. Cell Mol. Biol. 2013, 48, 550–558. [Google Scholar] [CrossRef] [Green Version]
  35. Rangarajan, S.; Bone, N.B.; Zmijewska, A.A.; Jiang, S.; Park, D.W.; Bernard, K.; Locy, M.L.; Ravi, S.; Deshane, J.; Mannon, R.B.; et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat. Med. 2018, 24, 1121–1127. [Google Scholar] [CrossRef]
  36. Ohkita, M.; Tawa, M.; Kitada, K.; Matsumura, Y. Pathophysiological roles of endothelin receptors in cardiovascular diseases. J. Pharmacol. Sci. 2012, 119, 302–313. [Google Scholar] [CrossRef] [Green Version]
  37. Moravec, C.S.; Reynolds, E.E.; Stewart, R.W.; Bond, M. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem. Biophys. Res. Commun. 1989, 159, 14–18. [Google Scholar] [CrossRef]
  38. Katwa, L.C. Cardiac myofibroblasts isolated from the site of myocardial infarction express endothelin de novo. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H1132–H1139. [Google Scholar] [CrossRef] [Green Version]
  39. Shahar, I.; Fireman, E.; Topilsky, M.; Grief, J.; Schwarz, Y.; Kivity, S.; Ben-Efraim, S.; Spirer, Z. Effect of endothelin-1 on α-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int. J. Immunopharmacol. 1999, 21, 759–775. [Google Scholar] [CrossRef]
  40. Katwa, L.C.; Guarda, E.; Weber, K.T. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc. Res. 1993, 27, 2125–2129. [Google Scholar] [CrossRef]
  41. Gray, M.O.; Long, C.S.; Kalinyak, J.E.; Li, H.T.; Karliner, J.S. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblasts. Cardiovasc. Res. 1998, 40, 352–363. [Google Scholar] [CrossRef] [PubMed]
  42. Haynes, W.G.; Strachan, F.E.; Webb, D.J. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995, 92, 357–363. [Google Scholar] [CrossRef] [PubMed]
  43. Guarda, E.; Katwa, L.C.; Myers, P.R.; Tyagi, S.C.; Weber, K.T. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc. Res. 1993, 27, 2130–2134. [Google Scholar] [CrossRef]
  44. Abraham, D.J.; Vancheeswaran, R.; Dashwood, M.R.; Rajkumar, V.S.; Pantelides, P.; Xu, S.W.; du Bois, R.M.; Black, C.M. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 1997, 151, 831. [Google Scholar]
  45. Davie, N.; Haleen, S.J.; Upton, P.D.; Polak, J.M.; Yacoub, M.H.; Morrell, N.W.; Wharton, J. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 2002, 165, 398–405. [Google Scholar] [CrossRef]
  46. Sugden, P.H.; Clerk, A. Endothelin signalling in the cardiac myocyte and its pathophysiological relevance. Curr. Vasc. Pharmacol. 2005, 3, 343–351. [Google Scholar] [CrossRef]
  47. Kodama, H.; Fukuda, K.; Takahashi, T.; Sano, M.; Kato, T.; Tahara, S.; Hakuno, D.; Sato, T.; Manabe, T.; Konishi, F.; et al. Role of EGF receptor and Pyk2 in endothelin-1-induced ERK activation in rat cardiomyocytes. J. Mol. Cell. Cardiol. 2002, 34, 139–150. [Google Scholar] [CrossRef]
  48. Daub, H.; Ulrich Weiss, F.; Wallasch, C.; Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996, 379, 557–560. [Google Scholar] [CrossRef] [PubMed]
  49. Gyöngyösi, M.; Winkler, J.; Ramos, I.; Do, Q.T.; Firat, H.; McDonald, K.; González, A.; Thum, T.; Díez, J.; Jaisser, F.; et al. Myocardial fibrosis: Biomedical research from bench to bedside. Eur. J. Heart Fail. 2017, 19, 177–191. [Google Scholar] [CrossRef] [Green Version]
  50. Yang, X.; Chen, B.; Liu, T.; Chen, X. Reversal of myofibroblast differentiation: A review. Eur. J. Pharmacol. 2014, 734, 83–90. [Google Scholar] [CrossRef]
  51. Driesen, R.B.; Nagaraju, C.K.; Abi-Char, J.; Coenen, T.; Lijnen, P.J.; Fagard, R.H.; Sipido, K.R.; Petrov, V.V. Reversible and irreversible differentiation of cardiac fibroblasts. Cardiovasc. Res. 2014, 101, 411–422. [Google Scholar] [CrossRef] [Green Version]
  52. Nagaraju, C.K.; Robinson, E.L.; Abdesselem, M.; Trenson, S.; Dries, E.; Gilbert, G.; Janssens, S.; Cleemput, J.V.; Rega, F.; Meyns, B.; et al. Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure. J. Am. Coll. Cardiol. 2019, 73, 2267–2282. [Google Scholar] [CrossRef] [PubMed]
  53. Duangrat, R.; Parichatikanond, W.; Morales, N.P.; Pinthong, D.; Mangmool, S. Sustained AT1R stimulation induces upregulation of growth factors in human cardiac fibroblasts via Gαq/TGF-β/ERK signaling that influences myocyte hypertrophy. Eur. J. Pharmacol. 2022, 937, 175384. [Google Scholar] [CrossRef]
  54. Phosri, S.; Bunrukchai, K.; Parichatikanond, W.; Sato, V.H.; Mangmool, S. Epac is required for exogenous and endogenous stimulation of adenosine A2B receptor for inhibition of angiotensin II-induced collagen synthesis and myofibroblast differentiation. Purinergic Signal. 2018, 14, 141–156. [Google Scholar] [CrossRef]
  55. Mangmool, S.; Kyaw, E.T.H.; Nuamnaichati, N.; Pandey, S.; Parichatikanond, W. Stimulation of adenosine A1 receptor prevents oxidative injury in H9c2 cardiomyoblasts: Role of Gβγ-mediated Akt and ERK1/2 signaling. Toxicol. Appl. Pharmacol. 2022, 451, 116175. [Google Scholar] [CrossRef]
  56. Pandey, S.; Madreiter-Sokolowski, C.T.; Mangmool, S.; Parichatikanond, W. High glucose-induced cardiomyocyte damage involves interplay between endothelin ET-1/ETA/ETB receptor and mTOR pathway. Int. J. Mol. Sci. 2022, 23, 13816. [Google Scholar] [CrossRef]
  57. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
Ijms 24 04475 g001 550
Figure 1. Treatment with ET-1 induced cell proliferation, and α-SMA and collagen I synthesis in human cardiac fibroblasts. (A–D) Cells were treated with various concentrations of endothelin-1 (ET-1) for 24 h (A–C) and 48 h (D). (A) Cell proliferation was calculated as the percentage relative to control group, and expressed as the mean ± SD. (B) Proliferative capacity of fibroblasts was determined by Ki-67 immunofluorescence assay. Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar represents 10 µm. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar represents 10 µm. (D) Relative α-SMA and collagen I mRNA levels determined by qRT-PCR were calculated as fold over the vehicle-treated group, and expressed as the mean ± SD. Data are obtained from four independent repetitions (n = 4). * p < 0.05 versus vehicle.
Figure 1. Treatment with ET-1 induced cell proliferation, and α-SMA and collagen I synthesis in human cardiac fibroblasts. (A–D) Cells were treated with various concentrations of endothelin-1 (ET-1) for 24 h (A–C) and 48 h (D). (A) Cell proliferation was calculated as the percentage relative to control group, and expressed as the mean ± SD. (B) Proliferative capacity of fibroblasts was determined by Ki-67 immunofluorescence assay. Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar represents 10 µm. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar represents 10 µm. (D) Relative α-SMA and collagen I mRNA levels determined by qRT-PCR were calculated as fold over the vehicle-treated group, and expressed as the mean ± SD. Data are obtained from four independent repetitions (n = 4). * p < 0.05 versus vehicle.
Ijms 24 04475 g001
Ijms 24 04475 g002 550
Figure 2. ET-1 induced cell proliferation and overexpression of myofibroblast markers through the ETAR subtype. Cells were pretreated without or with ambrisentan (ETAR antagonist; 1 µM), BQ-788 (ETBR antagonist; 1 µM) or ambrisentan plus BQ-788 for 1 h before treatment with ET-1 for 24 h (A–C) or 12 h (D). (A) Cell proliferation was calculated as percentage relative to control group. (B) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. (D) Relative α-SMA and collagen I mRNA levels analyzed by qRT-PCR were calculated as the fold over the vehicle-treated group. Data were expressed as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Figure 2. ET-1 induced cell proliferation and overexpression of myofibroblast markers through the ETAR subtype. Cells were pretreated without or with ambrisentan (ETAR antagonist; 1 µM), BQ-788 (ETBR antagonist; 1 µM) or ambrisentan plus BQ-788 for 1 h before treatment with ET-1 for 24 h (A–C) or 12 h (D). (A) Cell proliferation was calculated as percentage relative to control group. (B) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. (D) Relative α-SMA and collagen I mRNA levels analyzed by qRT-PCR were calculated as the fold over the vehicle-treated group. Data were expressed as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Ijms 24 04475 g002
Ijms 24 04475 g003 550
Figure 3. ET-1-induced cell proliferation and synthesis of α-SMA and collagen I is mediated through ETAR/Gαq signaling. Cells were pretreated without or with FR900359 (Gq inhibitor; 5 µM), PTX (Gi/o inhibitor; 10 µM) or gallein (Gβγ inhibitor; 10 µM) for 1 h before treatment with 20 nM ET-1 for 24 h (A–C) or 12 h (D). (A) Cell proliferation was calculated as the percentage relative to control group. (B) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. (D) Relative α-SMA and collagen I mRNA levels determined by RT-qPCR were calculated as the fold over the vehicle-treated group. Data were expressed as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Figure 3. ET-1-induced cell proliferation and synthesis of α-SMA and collagen I is mediated through ETAR/Gαq signaling. Cells were pretreated without or with FR900359 (Gq inhibitor; 5 µM), PTX (Gi/o inhibitor; 10 µM) or gallein (Gβγ inhibitor; 10 µM) for 1 h before treatment with 20 nM ET-1 for 24 h (A–C) or 12 h (D). (A) Cell proliferation was calculated as the percentage relative to control group. (B) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. (D) Relative α-SMA and collagen I mRNA levels determined by RT-qPCR were calculated as the fold over the vehicle-treated group. Data were expressed as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Ijms 24 04475 g003
Ijms 24 04475 g004 550
Figure 4. Inhibition of ERK1/2 suppresses ET-1-induced cell proliferation and myofibroblast differentiation. Cells were pretreated without or with 1 µM FR180204 (ERK1/2 inhibitor; ERK inh), 1 µM SB203580 (p38 inhibitor; p38 inh), 1 µM SP600125 (JNK inhibitor; JNK inh) for 1 h before treatment with 20 nM ET-1 for 24 h (A–C) or 12 h (D). (A) Cell proliferation was calculated as the percentage relative to the control group. (B) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. (D) Relative α-SMA and collagen I mRNA levels determined by RT-qPCR were calculated as the fold over the vehicle-treated group. (E) Cells were pretreated without or with ambrisentan (1 µM), BQ-788 (1 µM) or ambrisentan plus BQ-788 for 1 h before treatment with ET-1 for 30 min. (F) Cells were pretreated without or with FR900359 (Gq inh; 5 µM), PTX (Gi/o inh; 10 µM) or gallein (Gβγ inh; 10 µM) for 1 h before treatment with ET-1 for 30 min. (E,F) Cells were pretreated without or with specific inhibitors for 1 h before treatment with 20 nM ET-1 for 30 min. ERK1/2 activation was assessed by the levels of phosphorylated ERK1/2 as compared to total ERK1/2 and calculated as the fold over the vehicle-treated group. Data were shown as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Figure 4. Inhibition of ERK1/2 suppresses ET-1-induced cell proliferation and myofibroblast differentiation. Cells were pretreated without or with 1 µM FR180204 (ERK1/2 inhibitor; ERK inh), 1 µM SB203580 (p38 inhibitor; p38 inh), 1 µM SP600125 (JNK inhibitor; JNK inh) for 1 h before treatment with 20 nM ET-1 for 24 h (A–C) or 12 h (D). (A) Cell proliferation was calculated as the percentage relative to the control group. (B) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. (D) Relative α-SMA and collagen I mRNA levels determined by RT-qPCR were calculated as the fold over the vehicle-treated group. (E) Cells were pretreated without or with ambrisentan (1 µM), BQ-788 (1 µM) or ambrisentan plus BQ-788 for 1 h before treatment with ET-1 for 30 min. (F) Cells were pretreated without or with FR900359 (Gq inh; 5 µM), PTX (Gi/o inh; 10 µM) or gallein (Gβγ inh; 10 µM) for 1 h before treatment with ET-1 for 30 min. (E,F) Cells were pretreated without or with specific inhibitors for 1 h before treatment with 20 nM ET-1 for 30 min. ERK1/2 activation was assessed by the levels of phosphorylated ERK1/2 as compared to total ERK1/2 and calculated as the fold over the vehicle-treated group. Data were shown as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Ijms 24 04475 g004
Ijms 24 04475 g005 550
Figure 5. Preventive effects of ERAs on ET-1-induced cell proliferation and myofibroblast differentiation. Cells were pretreated without or with ambrisentan (1 µM) or bosentan (1 µM) for 1 h before treatment with 20 nM ET-1 for 24 h (A–C) or 12 h (D). (A) Cell proliferation was calculated as the percentage relative to the control group. (B) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. (D) Relative α-SMA and collagen I mRNA levels determined by RT-qPCR were calculated as fold over the vehicle-treated group. Data were expressed as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Figure 5. Preventive effects of ERAs on ET-1-induced cell proliferation and myofibroblast differentiation. Cells were pretreated without or with ambrisentan (1 µM) or bosentan (1 µM) for 1 h before treatment with 20 nM ET-1 for 24 h (A–C) or 12 h (D). (A) Cell proliferation was calculated as the percentage relative to the control group. (B) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (C) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. (D) Relative α-SMA and collagen I mRNA levels determined by RT-qPCR were calculated as fold over the vehicle-treated group. Data were expressed as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Ijms 24 04475 g005
Ijms 24 04475 g006 550
Figure 6. Restorative effects of ERAs on ET-1-induced cell proliferation and α-SMA synthesis. (A) Schematic diagram representing timeline of cell culture and treatment. (B–D) Cells were treated with 20 nM ET-1 for 24 to induce myofibroblast differentiation. After treatment for 24 h, the media were changed to either ET-1 plus vehicle, ET-1 plus ambrisentan, or ET-1 plus bosentan. Cells were further cultured for 3 days. The analysis of cell proliferation and α-SMA expression was taken on day 1 or 3 after co-treatment. (B) Cell proliferation was calculated as the percentage relative to the control group. (C) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (D) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. Data were expressed as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Figure 6. Restorative effects of ERAs on ET-1-induced cell proliferation and α-SMA synthesis. (A) Schematic diagram representing timeline of cell culture and treatment. (B–D) Cells were treated with 20 nM ET-1 for 24 to induce myofibroblast differentiation. After treatment for 24 h, the media were changed to either ET-1 plus vehicle, ET-1 plus ambrisentan, or ET-1 plus bosentan. Cells were further cultured for 3 days. The analysis of cell proliferation and α-SMA expression was taken on day 1 or 3 after co-treatment. (B) Cell proliferation was calculated as the percentage relative to the control group. (C) Cells were stained for Ki-67 (green) and nucleus DAPI (blue). Scale bar, 10 µm. Proliferative capacity was calculated as the percentage of Ki-67-positive cells. (D) α-SMA protein expression was visualized by fluorescent microscope. Cells were stained for α-SMA (green) and nucleus DAPI (blue). Scale bar, 10 µm. Data were expressed as the mean ± SD. (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Ijms 24 04475 g006
Ijms 24 04475 g007 550
Figure 7. Schematic representing the ETAR/Gαq/ERK signaling pathway for ET-1-inducd fibroblast activation and myofibroblast differentiation. ET-1 binding to ETARs leads to an activation of heterotrimeric Gq protein, resulting in the dissociation of the Gαq protein from the Gβγ subunit. The activated Gαq proteins transduced the signal through ERK1/2, which in turn induced fibroblast activation and myofibroblast differentiation. Interestingly, ETR antagonism using ERAs, ambrisentan and bosentan, exhibits cardioprotective effects by prevention and restoration of fibrotic actions of ET-1 in human cardiac fibroblasts. α-SMA: α-smooth muscle actin; ET-1: Endothelin-1; ERAs: endothelin receptor antagonists.
Figure 7. Schematic representing the ETAR/Gαq/ERK signaling pathway for ET-1-inducd fibroblast activation and myofibroblast differentiation. ET-1 binding to ETARs leads to an activation of heterotrimeric Gq protein, resulting in the dissociation of the Gαq protein from the Gβγ subunit. The activated Gαq proteins transduced the signal through ERK1/2, which in turn induced fibroblast activation and myofibroblast differentiation. Interestingly, ETR antagonism using ERAs, ambrisentan and bosentan, exhibits cardioprotective effects by prevention and restoration of fibrotic actions of ET-1 in human cardiac fibroblasts. α-SMA: α-smooth muscle actin; ET-1: Endothelin-1; ERAs: endothelin receptor antagonists.
Ijms 24 04475 g007
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Duangrat, R.; Parichatikanond, W.; Likitnukul, S.; Mangmool, S. Endothelin-1 Induces Cell Proliferation and Myofibroblast Differentiation through the ETAR/Gαq/ERK Signaling Pathway in Human Cardiac Fibroblasts. Int. J. Mol. Sci. 2023, 24, 4475. https://doi.org/10.3390/ijms24054475

AMA Style

Duangrat R, Parichatikanond W, Likitnukul S, Mangmool S. Endothelin-1 Induces Cell Proliferation and Myofibroblast Differentiation through the ETAR/Gαq/ERK Signaling Pathway in Human Cardiac Fibroblasts. International Journal of Molecular Sciences. 2023; 24(5):4475. https://doi.org/10.3390/ijms24054475

Chicago/Turabian Style

Duangrat, Ratchanee, Warisara Parichatikanond, Sutharinee Likitnukul, and Supachoke Mangmool. 2023. "Endothelin-1 Induces Cell Proliferation and Myofibroblast Differentiation through the ETAR/Gαq/ERK Signaling Pathway in Human Cardiac Fibroblasts" International Journal of Molecular Sciences 24, no. 5: 4475. https://doi.org/10.3390/ijms24054475

APA Style

Duangrat, R., Parichatikanond, W., Likitnukul, S., & Mangmool, S. (2023). Endothelin-1 Induces Cell Proliferation and Myofibroblast Differentiation through the ETAR/Gαq/ERK Signaling Pathway in Human Cardiac Fibroblasts. International Journal of Molecular Sciences, 24(5), 4475. https://doi.org/10.3390/ijms24054475

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop